Phillips-Medisize, in collaboration with its customer, Ascendis Pharma, was recently recognized with a third industry award for the Skytrofa Auto-Injector. The Red Dot Award recognizes the drug ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

SINGAPORE, May 29, 2025 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce the Australian registration of SKYTROFA® (lonapegsomatropin) as a new ...

Ascendis Pharma announced that the US Food and Drug Administration (FDA) has approved Skytrofa (lonapegsomatropin-tcgd) for the treatment of pediatric patients one year and older who weigh at least 11 ...

Skytrofa is a brand-name injection prescribed for growth hormone deficiency (GHD) in children. Skytrofa contains the active ingredient lonapegsomatropin and belongs to the growth hormone drug class.

Skytrofa is a long-acting form of somatropin. Somatropin is also called human growth hormone. Skytrofa is also considered a pegylated somatropin product. Pegylated means the medication is attached to ...

COPENHAGEN, Denmark, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to potentially create new ...

SKYTROFA ® (lonapegsomatropin) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of paediatric growth hormone deficiency. [1] "We are delighted to have secured TGA ...

SKYTROFA ® (lonapegsomatropin) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of paediatric growth hormone deficiency. [1] SINGAPORE, May 29, 2025 /PRNewswire/ -- ...

"We are delighted to have secured TGA registration of SKYTROFA for eligible Australian children with growth hormone deficiency. Beyond short stature, children and adolescents with the condition may ...